Bovie Medical Corp. (NYSE:BVX) announced a flurry of personnel moves in its corner office and board room.
The company said current president and CEO Andrew Makrides will relinquish his title of president but keep his position as chief executive. J. Robert Saron, the firm’s chief sales and marketing officer, will assume the role of president. Saron formerly served as Bovie’s CEO from 1994 through 1998.
In addition, the company elected Lawrence Waldman and Michael Geraghty its board of directors, while accepting the resignation of Dr. Peter Pardoll who stepped down on March 18, according to regulatory filings.
Waldman is the executive vice president of sales at Optos Inc. (LON:OPTS), while Geraghty is a partner at the accounting firm Holtz Rubenstein Reminick LLP.
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
- Rubbermaid Medical Solutions expands in Canadian
Rubbermaid Medical Solutions (RMS) announced the addition of Joe Teodoro to its sales force. In his new role, Teodoro will be responsible for expanding RMS’ Canadian presence.
- NeuroMetrix names diabetic neuropathy SAB
NeuroMetrix, Inc. (NSDQ:NURO) formed a scientific advisory board to help guide the development of its diabetic peripheral neuropathy (DPN) test. The device is a modified version of the company’s NC-stat nerve conduction study system. It is designed to quickly, accurately, and cost-effectively measure sural nerve conduction velocity, a well established quantitative biomarker for DPN, thereby providing the opportunity for earlier and better targeted clinical intervention.
- bluebird bio appoints SAB
bluebird bio, a developer of gene therapies for genetic disorders, announced the appointment of leading experts to its newly formed scientific advisory board. The newly appointed SAB will serve as a resource to bluebird bio as it continues to develop therapies for severe genetic disorders.
- BD appoints new African GM
Peter Mehlape, till recently general manager of the Southern African operations of the global medical technology firm Becton, Dickinson & Co. (NYSE:BDX) has been appointed as the general manager for the company’s entire business in the southern and east African region, reports Africa Science News.
- CCS names new CEO
CCS Medical announced that its Board of Directors has appointed Dirk Allison President and Chief Executive Officer for CCS Medical effective immediately. Mr. Allison has been the interim CEO of the Company since November 2010.
- Boston Scientific exec named BridgePoint Medical CEO
Denis Harrington, who until recently was head of sales for Boston Scientific Corp.’s (NYSE:BSX) cardiovascular and CRM business, has left the company to become president and CEO of a Twin Cities startup called BridgePoint Medical Inc., reports MedCity News.
- Mindray appoints Jie Liu CFO
Mindray Medical International Ltd. (NYSE:MR) named Jie Liu as CFO of the ompany effective as of April 30. He succeeds Ronald Ede. Ede will step down from the role of CFO to pursue other personal interests, but will remain with Mindray as a director on Mindray’s board. Liu will also remain as Mindray’s COO at the same time.
- CJPS to add sales and clinical personnel
CJPS Medical Systems wants to hire approximately 30 new employees to intensify its sales efforts in the U.S., at its new Auburn Hills, MI facility for its homecare patient monitor.
- Paul Ross appointed GenMark CFO
GenMark Diagnostics Inc. (NSDQ:GNMK) announced that it has appointed Mr. Paul Ross as CFO, effective April 4. Mr. Ross joins the company from Teledata Technology Solutions, a global provider of information technology consulting services, where he serves as the chief financial officer.
- Morgan Keegan taps medical devices analyst Jan Wald
Morgan Keegan & Company Inc. announced that Jan Wald joined the firm as a senior equity research analyst following the medical device industry. Wald, who is based in the firm’s Boston, Mass. office, joins Morgan Keegan from Noble Financial Group. Wald was also formerly a managing director and medical technology analyst at the Stanford Group Company, A.G. Edwards and George K. Baum. At A.G. Edwards, he was also the Healthcare Group Leader.
- Nevro appoints Michael DeMane CEO
Nevro Corp. appointed Michael DeMane as CEO. He will also join the company’s Board of Directors. DeMane is a veteran medical device company executive, having held leadership roles in the U.S., Europe and Australia over the past 30 years. His most recent operating role was COO of Medtronic Inc. (NYSE:MDT).
- Why J&J CEO got a pay bump
There are two ways to look at the 2010 compensation package given Johnson & Johnson (NYSE:JNJ) CEO Bill Weldon. On one hand, the J&J board cut his overall take home by 7 percent, to $28.7 million from $30.8 million, since his performance bonus was slashed – by 45 percent to $1.98 million – thanks to all those product recalls and subsequent fallout among some consumers, investors and industry watchers. In other words, he suffered. On the other hand, Bill received a 3 percent merit raise, as noted previously (see here), according to Seeking Alpha.
- SeraCare Life Sciences taps O’Connor for VP of sales and marketing
SeraCare Life Sciences, Inc. (NSDQ:SRLS) appointed Sean O’Connor as vice president of sales and marketing. In this position, Mr. O’Connor will be responsible for aligning and optimizing all sales and marketing operations at SeraCare.
- Rudko resigns from PLC board
On March 11, Robert Rudko notified PLC Systems Inc. (OTC:PLCSF) that he was resigning as a member of the the company’s Board of Directors, effective immediately. There were no disagreements between Rudko and the company on any matter relating to the registrant’s operations, policies or practices which resulted in his resignation, according to an SEC filing.
- J.C. Scott tapped for AdvaMed government affairs post
The Advanced Medical Technology Association announced that J.C. Scott will join the organization as senior executive vice president and director of its bipartisan government affairs department effective April 11.